A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach
Abstract Introduction The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [14C]-AG-221. Methods This was a phase 1, open-label study. Si...
Main Authors: | Xiaomin Wang, Jian Chen, Josephine Reyes, Simon Zhou, Maria Palmisano, Yan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-07-01
|
Series: | Oncology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s40487-019-0097-7 |
Similar Items
-
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
by: Min Ruan, et al.
Published: (2021-02-01) -
Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
by: Federica Lessi, et al.
Published: (2021-08-01) -
Long Noncoding RNA SOCS2-AS Promotes Leukemogenesis in FLT3-ITD+ Acute Myeloid Leukemia Through miRNA-221
by: Zhang R, et al.
Published: (2020-04-01) -
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
by: Michael J. Buege, et al.
Published: (2018-06-01) -
Название
by: IG Budaeva, et al.
Published: (2019-05-01)